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Abstract: Response to chemoradiotherapy (CRT) in patients with locally advanced rectal cancer
(RC) is quite variable and it is urgent to find predictive biomarkers of response. We investigated
miR-21 as tissue and plasma biomarker of response to CRT in a prospective cohort of RC patients;
The expression of miR-21 was analyzed in pre- and post-CRT rectal tissue and plasma in 37 patients
with RC. Two groups were defined: Pathological responders (TRG 0, 1 and 2) and non-responders
(TRG 3). The association between miR-21, clinical and oncological outcomes was assessed; miR-21
was upregulated in tumor tissue and we found increased odds of overexpression in pre-CRT tumor
tissue (OR: 1.63; 95% CI: 0.40–6.63, p = 0.498) and pre-CRT plasma (OR: 1.79; 95% CI: 0.45–7.19,
p = 0.414) of non-responders. The overall recurrence risk increased with miR-21 overexpression in
pre-CRT tumor tissue (HR: 2.175, p = 0.37); Significantly higher miR-21 expression is observed in
tumor tissue comparing with non-neoplastic. Increased odds of non-response is reported in patients
expressing higher miR-21, although without statistical significance. This is one of the first studies on
circulating miR-21 as a potential biomarker of response to CRT in RC patients.
Keywords: biomarkers; miR-21; chemoradiotherapy; rectal cancer; therapy response; tumor
regression grade
1. Introduction
Rectal cancer (RC) is one of the most prevalent cancers in the world [1] but, despite great progress
in treatment options, chemoradiotherapy (CRT) is still ministered in the majority of locally advanced
cases [2]. After neoadjuvant treatment, almost 30% of patients exhibit resistance to CRT having no
benefit from this therapy [3]. In fact, non-responders are at increased risk of disease progression and
toxicity related to CRT. Currently, we cannot predict response and the complications associated with
this treatment should not be underestimated. There is an urgent need to identify patients that will not
benefit from CRT and thus avoid unnecessary morbidity.
MicroRNAs (miRNAs) are highly conserved non-coding RNAs with a post-transcriptional function
of inhibiting mRNA translation. These molecules seem to regulate carcinogenic pathways and the
potential role in oncogenesis hypothesized their use as biomarkers in cancer diagnostic and prediction
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of response to therapy [4]. In fact, miRNAs associated with colorectal cancer (CRC) have been identified
in tumor tissue, however, the need for a non-invasive prediction tool prompted their investigation in
serum and plasma as circulating markers.
One of the most studied miRNAs is oncomiR-21, demonstrated as a potential diagnostic and
prognostic biomarker for CRC, often up-regulated in serum and solid tumors [5–13]. In CRC, miR-21
up-regulation has been related to advanced stage, positive lymph nodes, venous invasion, and
metastatic behavior [10–12,14]. Indeed, miR-21 plays a key role in several biological processes needed
for tumorigenesis, including resistance to apoptosis, proliferation, evasion to growth suppressors,
replicative immortality, and tumor promoting inflammation [15]. miR-21 oncogenic function is exerted
mainly through the suppression of a large number of genes that participate directly or indirectly in the
extrinsic or intrinsic apoptosis pathways (PDCD4, PTEN, TPM1, MARCKS, HNRPK, TP63, IL12A,
JAG1, BTG2, LRRFIP1, BMPR2, TGFBR2, CDC25A, PELI1, ANKRD46, CDK2AP1, MEF2C, MSH2,
MSH6, PPARA, RASGRP1, FASLG, TIMP3, ANP32A, SMARCA4, and THRB). In addition, miR-21 is
also a negative regulator of p53 signaling and promotes NF-kB, implicated in deregulation of glucose
flux and oxidative phosphorylation [15].
However, in rectal cancer (RC) the role of miR-21 as predictor of response to CRT and its association
with oncological outcomes has not been fully elucidated. Although one study has demonstrated
overexpression of miR-21 in pre-CRT tumor tissue of patients with complete pathological response [16],
others have shown that high miR-21 levels associated with worse pathological response, discriminating
responders from non-responders [17,18]. Moreover, we have also identified, in a retrospective study,
an association between miR-21 expression in pre-CRT rectal tumor tissue and tumor regression grade
(TRG), with higher levels correlating with worse pathological response [19]. On the other hand, scarce
studies have investigated the potential of circulating miR-21 as a molecular predictor of response in
the neoadjuvant therapy setting.
In the present study, using a prospective cohort of patients with RC, we investigated the relation
between tissue and plasma miR-21 and evaluated its potential use as a tissue and circulating biomarker
of response to CRT. The association between miR-21 and clinical and oncological outcomes was
also assessed.
2. Results
2.1. Patient Clinical Parameters
Clinical and demographic features of all 37 patients are summarized in Table 1.
Table 1. Patient clinical parameters.
Clinical Parameters Patients (n = 37)
Gender, n (%) Male 25 (68)
Female 12 (32)
Age, median 62 (42–88)
BMI, median 25 (20–35)











Tumor location (%) 1/3 superior 1 (3)
1/3 medium 14 (38)
1/3 inferior 22 (59)
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Table 1. Cont.
Clinical Parameters Patients (n = 37)
Tumor extension (mm), median 55 (19–90)
Distance to anal verge (mm), median 50 (0–100)




cN 0 3 (8)
+ 34 (92)
cM 0 35 (95)
1 2 (5)





EMVI, n (%) Negative 25 (68)
Present 12 (32)




CEA (mg/mL), median 1.7 (0.5–96)
CRT 5-FU based 4 (11)
Capecitabine based 33 (90)




BMI: Body Mass Index; ASA: American Society of Anesthesiologists; CRM: circumferential resection margin; EMVI:
extramural vascular invasion; CEA: carcinoembrinonary antigen; CRT: chemoradiotherapy; MR: magnetic resonance;
TRG: tumor regression grade; CAP: College of American Pathologists.
2.2. miR-21 Expression in Responders and Non-Responders
miRNA expression profile was analyzed in non-neoplastic and tumor rectal tissues as well as in
plasma, collected before and after CRT. The differences observed when comparing responders (TRG 0-2)
and non-responders (TRG 3) are demonstrated in Figure 1. In responders, miR-21 revealed significantly
higher expression (p = 0.0013) in pre-CRT tumor tissue when compared with non-neoplastic tissue.
The same expression profile was observed in post-CRT tissue samples with higher levels of miR-21 in the
tumor tissue. However, this profile was also detected in non-responders with overexpression of miR-21
detected in pre-CRT (p = 0.0004) and post-CRT tumor tissue when compared with non-neoplastic
tissue (Figure 1A).
Regarding miR-21 expression analysis in plasma (Figure 1B), a slight increase with no statistical
significance was observed in post-CRT plasma miR-21 expression in responders comparing with
pre-CRT samples. Again, no differences were evident before and after treatment in non-responders.
2.3. Clinical Parameters and TRG
There was no statistically significant association between clinical parameters and TRG (Table 2).
Nevertheless, we observed in our sample a reduced odds of non-response (TGR 3) in women (OR:
0.54; CI: 0.13–2.27; p = 0.4), individuals older than 60 years (OR: 0.39; CI: 0.09–1.74; p = 0.217), ASA 3
(OR: 0.8; CI: 0.21–3.03; p = 0.746), in patients treated with capecitabine based CRT when compared to
5-FU (OR: 0.34; CI: 0.03–4.32; p = 0.390) and tumors located in the inferior 1/3 of the rectum (OR: 0.79;
CI: 0.21–2.97; p = 0.73). On the other hand, the odds of non-response were 6 times higher for cT3 and
T4 when compared to cT1 or cT2 (OR: 6.0; CI: 0.64–56.06, p = 0.09).
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Figure 1. Expression profile of miR-21 in pre- and post-CRT samples in responders (TRG 0-2) and 
non-responders (TRG 3). (a) miR-21 levels in non-neoplastic and tumor tissues; (b) miR-21 levels in 
plasma. Fold changes in tissue and plasma miR-21 expression are calculated from pre-CRT non-
neoplastic tissue and pre-CRT plasma expression, respectively. Data are mean ± SEM. N corresponds 
to non-neoplastic tissue and T to tumor tissue. ** p ≤ 0.01, *** p ≤ 0.001. 
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Figure 1. Expression profile of miR-21 in pre- and post-CRT samples in responders (TRG 0-2)
and non-responders (TRG 3). (a) miR-21 levels i n n-neoplastic and tumor tissues; (b) miR-21
levels in plasma. Fold changes in tissue and plasma miR-21 expression are calculated from pre-CRT
non-neoplastic tissue and pre-CRT plasma expression, respectively. Data are mean±SEM. N corresponds
to non-neoplastic tissue and T to tum r tissue. ** p ≤ 0.01, *** p ≤ 0.001.
able 2. Clinical parameters and TRG.
Simple Logistic Regressio OR 95% CI p Value
Continuous Variables
BMI 1.029 0.2649–3.993 0.968
Age 0.392 0.0887–1.735 0.217
Categorical Variables
Gender





Inferior 1/3 0.791 0.2107–2.972 0.732
ASA
1 + 2
3 0.800 0.2114–3.028 0.746
CRM MR
Free
Threatened, invaded 1.169 0.3162–4.320 0.817
Extramesorectal nodes
Negative
Positive 0.542 0.1291–2.272 0.406
cT
T1-2
T3-4 6.000 0.6421–56.062 0.090
cN
0
+ 0.350 0.0289–4.246 0.399
cM
0
1 1.333 0.0770–23.085 0.845
Chemotherapy Capecitabine 0.342 0.0280–4.320 0.390
5-FU
Simple logistic regression analysis using TRG as dependent variable (TRG 3) and clinical/ molecular variables as
independent variables. OR: odds ratio of non-response (TRG 3); TRG: Tumor regression grade; CI: confidence
interval; BMI: body mass index; ASA: American Society of Anesthesiologists; CRM: circumferential resection margin;
MR: magnetic resonance.
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2.4. miR-21 Expression and TRG
To study a possible association between miR-21 expression and TRG, we resorted to ROC curve
analysis to determine the optimal cut-off that maximized sensitivity, specificity and distinction between
responders and non-responders (Table S1). We found increased odds of non-response in patients
with higher miR-21 expression (>1.2) in pre-CRT non-neoplastic rectal tissue (OR: 1.2; CI: 0.24–6.06,
p = 0.828) and in patients with levels higher than 2.61 in pre-CRT tumor tissue (OR: 1.6; CI: 0.40–6.63,
p = 0.49) (Table 3).
Table 3. miR-21 expression and TRG.
















>0.84 1.09 0.276–4.330 0.900
Simple logistic regression according to cut-offs determined with ROC curve analysis. OR: odds ratio of non-response
(TRG 3); CI: confidence interval.
Regarding plasmatic miR-21, there was also an increased odds of TRG 3 in patients with pre-CRT
miR-21 expression higher than 0.54 (OR: 1.2; CI: 0.24–6.06, p = 0.828) and in patients with post-CRT
miR-21 levels >0.84 (OR: 1.09; CI: 0.28–4.33, p = 0.9) (Table 3).
Overall, in our sample, patients with higher levels of miR-21 in pre-CRT tissue and plasma had
less response to CRT.
2.5. Clinical Parameters and miR-21 Expression in Pre-CRT Tumor Tissue and Plasma
In pre-CRT tumor tissue an increased odds of miR-21 overexpression (>2.61 fold change) was
observed in patients with cT3-4 (OR: 2.71; 95% CI: 0.44–16.68, p = 0.28), TRG 3 (OR: 1.63; 95% CI:
0.40–6.63, p = 0.498), local (OR: 1.14; 95% CI: 0.07–20.02, p = 0.928) and distant recurrence (OR: 2.73;
95% CI: 0.42–17.65, p = 0.289). On the contrary, high miR-21 levels were less likely for subjects older
than 60 years (OR: 0.83; 95% CI: 0.19–3.72, p = 0.81), obese (OR: 0.38; 95% CI: 0.08–1.69, p = 0.21) and
ASA 3 (OR: 0.41; 95% CI: 0.09–1.81, p = 0.24) (Table 4).
Regarding pre-CRT circulating miR-21, there was an increased probability of miR-21 overexpression
(>0.54 fold change) in patients with TRG 3 (OR: 1.79; 95% CI: 0.45–7.19, p = 0.414), N+ (OR: 1.75; 95%
CI: 0.14–21.44, p = 0.663) and distant metastasis (OR: 2.21; 95% CI: 0.07–21.22, p = 0.896). However,
overexpression was less likely in obese patients (OR: 0.89; 95% CI: 0.22–3.66, p = 0.87), cT3 and cT4 (OR:
0.80; 95% CI: 0.14–4.70, p = 0.80) and in the presence of distant recurrence (OR: 0.30; 95% CI: 0.07–2.45,
p = 0.32) (Table 5). Again, overall, patients with miR-21 overexpression in pre-CRT tumor tissue and in
blood had less response to CRT.
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Table 4. Clinical parameters and miR-21 expression in pre-CRT tumor tissue.
Variables OR 95% CI p Value
Age <60
≥60 0.83 0.19–3.72 0.814
Sex
Male
Female 2.1 0.49–8.99 0.322
BMI
Low weight + normal
Pre-obesity + obesity 0.38 0.08–1.69 0.206
ASA score
2
3 0.41 0.09–1.81 0.242
Stage pre-CRT I + II
III + IV 0.88 0.57–27.24 0.203
cT
T1
T3 + 4 2.71 0.44–16.68 0.280
cN
0
1 0.87 0.05–15.33 0.928
pTRG TRG 0 + 1 + 2
TRG 3 1.63 0.40–6.63 0.498
Distant recurrence
No
Yes 2.73 0.42–17.65 0.289
Local recurrence
No
Yes 1.14 0.07–20.02 0.928
Simple logistic regression analysis using miR-21 expression (> 2.61-fold change) as dependent variable and clinical
variables as independent variables. OR of miR-21 > 2.61-fold change. OR: odds ratio; CI: confidence interval; ASA:
American Society of Anesthesiologists; BMI: body mass index; CRT: chemoradiotherapy; pTRG: pathological tumor
regression grade.
Table 5. Clinical parameters and miR-21 expression in pre-CRT plasma.
Variables OR 95% CI p Value
Age <60
≥60 4.14 0.71–24.16 0.106
Sex
Male
Female 1.73 0.40–7.46 0.465
BMI
Low weight + normal
Pre-obesity + obesity 0.89 0.22–3.66 0.873
ASA score
2
3 1.75 0.43–7.17 0.442
Stage pre-CRT I + II
III + IV 0.82 0.05–14.39 0.896
cT
T1 + T2
T3 + T4 0.80 0.14–4.70 0.808
cN
N0
N1 1.75 0.14–21.44 0.663
cM
M0
M1 2.21 0.07–21.22 0.896
pTRG TRG 0 + 1 + 2
TRG 3 1.79 0.45–7.19 0.414
Distant recurrence
No
Yes 0.40 0.07–2.45 0.320
Simple logistic regression analysis using miR-21 expression (>0.54-fold change) as dependent variable and
clinical variables as independent variables. OR of miR-21 > 0.54. OR: odds ratio; CI: confidence interval; ASA:
American Society of Anesthesiologists; BMI: body mass index; CRT: chemoradiotherapy; pTRG: pathological tumor
regression grade.
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2.6. miR-21 Expression and Oncological Outcomes
With a median follow up of 603 (196–1007) days, we report 3 (8%) mortality cases, 2 (5%) cases of
local recurrence (LR) and 7 (19%) of distant recurrence (DR). The low number of death cases precluded
correct estimation of overall survival (OS) but 3 and 5-year predicted disease free survival (DFS) were
67 and 46%, respectively (Figure 2).
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Figure 2. Overall disease-free survival (DFS) and according to clinical and oncological parameters.
Kaplan–Meier curves estimating 3-year overall DFS in patients expressing miR-21 and according to
age, gender, disease stage, M stage, N stage, T stage, mesorectal tumor deposits (N1c), histological
grade, tumor location, circumferential resection margin, extramural vascular invasion (EMVI), pre-CRT
non-neoplastic tissue miR-21, pre-CRT tumor tissue miR-21, pre-CRT plasma miR-21 and post-CRT
plasma miR-21.
The overall recurrence hazard risk (HR) increased in women (HR: 1.218, p = 0.797), older patients
(HR: 1.64, p = 0.65), lower tumor location (HR: 4.03, p = 0.19), threatened or invaded circumferential
resection margin (CRM) (HR: 2.14, p = 0.37) and TRG 3 (HR: 3.95, p = 0.11) (Table 6). Overall recurrence
Pharmaceuticals 2020, 13, 246 8 of 14
HR also augmented in individuals with higher pre-CRT tumor tissue miR-21 expression (HR 2.175,
p = 0.37) (Table 6).
Table 6. Clinical parameters, miR-21 levels, and overall recurrence.
Variables Total DFS r Mean
Simple Cox Proportional Hazard Model
HR p Value
Tumor location
Superior + medium 15 1 2.53
4.027 0.199Inferior 22 6 2.25
Age <60 10 1 2.54 1.637 0.651
≥60 27 6 2.38
Gender
Male 25 4 2.41
1.218 0.797Female 12 3 2.39
CRM
Free 17 2 2.53
2.135 0.368Threatened/invaded 20 5 2.30
TRG
0–2 21 2 2.57
3.950 0.1083 16 5 2.21
miR-21
pre-CRT tumor
≤2.61 17 2 2.47
2.175 0.37
>2.61 15 4 2.26
miR-21
pre-CRT plasma
≤0.54 18 5 2.27
0.464 0.36
>0.54 15 2 2.45
Simple Cox Proportional Hazards Model using global recurrence as dependent variable and clinical parameters as
independent variables. HR: hazard ratio; CRM: circumferential resection margin; TRG: tumor regression grade;
DFS: disease free survival.
As expected, there was an impact in 3-year DFS in relation to histological grade (p = 0.09) and
distant metastasis (p = 0.029) (Figure 2) but no influence was noted in age, gender, T or N stage,
tumor location, threatened or invaded CRM, N1c or EMVI. There was also a decrease in 3-year DFS in
patients with higher pre-CRT tumor miR-21 (p = 0.36) and in patients with lower miR-21 in pre-CRT
non-neoplastic tissue (p = 0.09) and plasma (p = 0.14).
We also evaluated the correlation between pre- and post-CRT circulating and tissue miR-21.
Results showed, however, very week correlations (Figure S1). There was a positive but frail correlation
between pre-CRT plasma and tumor miR-21 with an increase in tissue miR-21 with escalation expression
in blood (r = 0.002, p = 0.993).
3. Discussion
The interest in identifying biomarkers for cancer has led both researchers and clinicians to focus
on miRNAs [20]. Some studies have investigated the diagnostic and prognostic value of miR-21 in RC
as well as its potential to predict response to CRT [16–18]. However, the conclusions obtained from
these studies were inconsistent granting the need to further explore the clinical significance of miR-21
as a biomarker in this setting. Generally, findings associate a superior miR-21 expression with a non-or
incomplete response. In fact, in a previous retrospective study, our group also identified an association
between miR-21 overexpression in pre-CRT rectal tumor tissue and worse pathological response [19].
In that study, this miRNA could differentiate incomplete from complete responders and potentially be
used as biomarker to predict TRG. Nevertheless, the evaluation of circulating miR-21 as a non-invasive
biomarker of response to CRT in rectal cancer has never been investigated.
The first detection of miRNAs in body fluids occurred when miR-21 was found in the serum of
B-cell lymphoma patients [21]. Since then, up-regulated miR-21 levels in plasma have been associated
with solid cancers (glioblastoma, breast cancer, and pancreatic cancer) [22] and therefore it was
termed oncomiR.
Levels of miRNAs in plasma are remarkably stable, reproducible, consistent among individuals
of the same species [23] and cells actively release the majority of circulating miRNAs. The idea of a
correlation between circulating and tissue miRNA supports the hypothesis that plasmatic miRNAs can
serve as biomarkers of disease or disease response. miRNAs appear to demonstrate the same change
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in expression, either increased or decreased, in plasma or serum and tumor tissues of patients with
various types of cancer [23]. However, only few studies focused on the detection of circulating miRNAs
in CRC patients [24–26] and this could be attributed to challenges in plasma miRNA extraction and
lack of consensus about internal controls for qRT-PCR and normalization.
Clinical significance of circulating miR-21 levels in CRC remains, in fact, not fully understood.
Some studies report on seric miR-21 as a discriminative biomarker of colorectal neoplasms from
healthy controls [9,27–37] and from benign or premalignant adenoma [33,38]. Circulating miR-21 has
also been correlated with tumor size, grade of differentiation, invasion, metastasis [32], recurrence,
and survival [6]. The expression of miR-21 has been found significantly increased in preoperative
serum from CRC patients who did not received neoadjuvant therapy and this correlated with tumor
size, poor survival, and lymph node metastasis [14,37]. Another important issue is that, in reality, very
few studies differentiate between colon and rectal cancer patients and these are two different entities
with distinct treatment options. In fact, serum miR-21 levels seem to be upregulated in rectum cancer
tissue in comparison to colon cancer [39].
In the present work, we aimed to investigate the potential of tissue miR-21 as a biomarker of
response to CRT in a prospective cohort of RC patients and validate our previous retrospective results
as well as assess circulating miR-21 in this setting. Although we could not demonstrate the efficacy of
tissue and plasma miR-21 to differentiate responders (TRG 0-2) from non-responders (TRG 3), we did
find an odds increase of non-response in all patients expressing higher miR-21 levels. miR-21 was
upregulated in tumor tissue and there was an increased probability of pre-CRT tumor tissue miR-21
overexpression in patients with non-response. In addition, in this study overall recurrence hazard
risk increased in patients with less response, threatened or invaded CRM, and higher pre-CRT tumor
tissue miR-21 levels. Regarding 3-year DFS analysis, we observed a decrease in survival in patients
with higher miR-21 levels in pre-CRT tumor tissue, while overexpression of miR-21 was related to a
better survival in pre-CRT non-neoplastic tissue. This is concordant with our hypothesis that when
comparing pre-CRT non-neoplastic and tumor tissue we predict response to treatment, where higher
miR-21 in pre-CRT tumor tissue in comparison with non-neoplastic tissue is indicative of a worse
response to treatment, whereas higher miR-21 in pre-CRT non-neoplastic tissue is associated with
better response to CRT. Considering plasma miR-21 analysis, although with no statistical significance,
we observed increased odds of pre-CRT circulating miR-21 overexpression in non-responders (TRG 3).
Overall, these results are in line with our retrospective study that found a significant association of
miR-21 overexpression in pre-CRT rectal cancer tissue with worse response to neoadjuvant therapy [19].
Moreover, pre-CRT plasmatic miR-21 may be also related to less response. To our knowledge, this is
one of the first reports in which circulating miR-21 has been investigated as a predictive biomarker of
response to neoadjuvant CRT in rectal cancer.
Recently, it was observed that circulating exosomal miR-21 could distinguish chemotherapy
resistant from chemosensitive CRC patients [40]. This miRNA was shown to be upregulated in the
exossomes of chemoresistant CRC cell lines and in pre-chemotherapy exosomal serum of patients
that did not respond to treatment. These results are according to our suggestion that overexpression
of pre-CRT circulating miR-21 may be indicative of worse response to CRT in rectal cancer setting,
possibly related to the chemotherapy effect. Interestingly, in the present study we also observed a
reduced odd of non-response in patients treated with capecitabine based CRT when compared to 5-FU
(OR: 0.34; CI: 0.03–4.32; p = 0.390). In contrast to 5-FU-based therapies, very limited data is available
on miRNA expression and response to CRT with capecitabine. Nevertheless, this outcome lines up
with our retrospective study, where 5-FU-treated patients also presented reduced odds of incomplete
response (OR: 0.19; 95% CI: 0.03–1.12, p = 0.05).
The differences observed between the current work and our previous report, that showed the
potential of miR-21 as a discriminative biomarker of response to CRT, are probably due to the limitation
in sample size in this prospective study as well as the different TRG based definition of patient groups.
Besides, although this group of patients includes uniform sampling and treatment, there is a potential
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for intratumoral heterogeneity and thus, validation of our results in a larger cohort still needs to
be performed.
4. Materials and Methods
This was a prospective observational study. Written and signed informed consent for collection
and use of biological samples was obtained from all volunteer study participants prior to sample
collection. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki,
as reflected in a priori approval by the institutional Human Research Committee and Ethical Committee
(Hospital Beatriz Ângelo; 13 March 2017, Project Identification Number 0240). The study was registered
in the Portuguese Data Protection Agency.
4.1. Patients and Tissue Samples
A total of 37 patients diagnosed with RC (stage I-IV, American Joint Committee on Cancer, AJCC)
between April 2017 and June 2019 in the Surgical Department of Hospital Beatriz Ângelo (Loures,
Portugal) treated with long course CRT and proctectomy were eligible. Patients had a preoperative
staging with pelvic magnetic resonance (MR), thoraco-abdomino-pelvic computed tomography (CT)
and endoanal ultrasound when pelvic MR was not clinically possible. Histopathological features were
confirmed by pathological analysis and patients were staged according to TNM staging system (8th
edition, 2017). Patients with other histological types of rectal malignancy, not submitted to CRT or
surgical resection, pregnant or under the age of 18 were excluded.
Two groups of patients were defined: responders (TRG 0, 1, and 2) composed of a total of
21 patients and non-responders (TRG 3) composed of a total of 16 patients.
Fresh frozen tissue samples were collected before and after CRT, during pre-therapeutic
colonoscopy and from the protectomy specimen, respectively. Pre-CRT rectal tumor biopsies were
gathered from all patients but post-CRT tumor tissues were available only from patients without a
pathological complete response. To allow a direct comparison of rectal cancer to matched non-neoplastic
rectal mucosa, we collected corresponding adjacent (>1 cm distant) non-tumor tissue both in biopsies
and protectomy specimens. Retrieved tumor and non-neoplastic tissue underwent histological
confirmation by a pathologist. A fixed amount of tissue (80 µm) was extracted across samples,
immediately frozen with CO2 prior to storage at −80 ◦C. In addition, liquid biopsies (plasma) were
also collected from 33 patients, before and after CRT, at the time of pre-treatment staging colonoscopy
and 24 h after proctectomy. Peripheral blood was collected in vacutainer liquid EDTA 6-mL blood
collection tubes and peripheral blood cells and plasma were separated by density gradient separation.
Plasma was then stored and frozen at −80 ◦C until RNA extraction.
4.2. Neoadjuvant Treatment
All patients underwent neoadjuvant CRT that consisted of a total dose of 50.4 Gy of pelvic
irradiation, 5 times a week, with a daily fraction of 2 Gy using at least a four-field technique. Radiation
was delivered with capecitabine (825 mg/m2/day) or 5-fluoruocil (5-FU) (1000 mg/m2/ day on day 1 to
5 and days 29 to 33). Surgery was performed 10–12 weeks after CRT.
4.3. Assessment of Pathological Response
Pathology specimens were graded by Tumor Regression Grade (TRG) according to the College of
American Pathologists guidelines (CAP, TNM 7th edition). Two independent pathologists blinded to
patient clinical data evaluated TRG categorizing tumors in: TRG 0 or complete response (no viable
tumor cells), TRG 1 or moderate score (single cells or little groups of cancer cells), TRG 2 or minimal
response (residual cancer outgrown by fibrosis), TRG 3 or poor response (minimal or no tumor killing
with extensive residual cancer).
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4.4. Follow up
Patients had a median of 603 (196–1007) days of follow up with no patients lost.
4.5. RNA Isolation from Fresh Frozen Tissues and Serum
Total RNA was extracted using RibozolTM reagent (VWR International, Radnor, PA, USA) in
pre- and post-CRT fresh frozen non-neoplastic and tumor rectal tissues samples according to the
manufacturer’s instructions, whereas miRNeasy serum/plasma advanced kit (Qiagen, GmbH, Germany)
was used to isolate RNA in pre- and post-CRT plasma samples from a total amount of 200 µL of
plasma. In plasmatic RNA isolation, an exogenous control was added to each sample to monitor
extraction efficiency and to further normalize miRNA expression data. Thus, 1.6x108 copies/µL of
synthetic spike-in control Caenorhabditis elegans miR-39 5’-phosphorylated (cel-miR-39-3p_5P) was
added according to the miRNeasy kit instructions. RNA extracted from tissue and serum was eluted
in 50 µL and 20 µL of RNase-free water, respectively. For a better evaluation of miRNAs quantity in
total RNA, the concentration of miRNA was determined using QubitTM miRNA Assay kit (Invitrogen,
ThermoFisher Scientific, Waltham, MA, USA). All RNA samples were stored at −80 ◦C.
4.6. cDNA Synthesis and Real-Time PCR (RT-PCR)
cDNA synthesis was performed using TaqMan® Advanced miRNA cDNA synthesis kit (Applied
Biosystems, ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.
Briefly, 2 µL of total RNA (corresponding to 2 ng of RNA extracted from tissue) were extended by
a 3′ poly-A tailing reaction and a 5′ adaptor ligation to the mature miRNAs. miRNAs were reverse
transcribed into cDNA by reverse transcription using Universal RT primers. In order to improve
detection of low-expressing miRNA targets, a pre amplification of the cDNA was performed using the
Universal miR-Amp Primers and miR-Amp Master Mix to uniformly increase the amount of cDNA
for each target, maintaining the relative differential expression levels. cDNA samples were stored at
-20◦C. Real-Time PCR was performed on a QuantstudioTM 7 Flex real-time PCR instrument (Applied
Biosystems, ThermoFisher Scientific, Waltham, MA, USA) with TaqManTM Advanced microRNA
Assays (Applied Biosystems, ThermoFisher Scientific, Waltham, MA, USA) to assess the expression
profile of hsa-miR-21-5p (Assay ID 477975_mir). All reactions were performed in duplicate.
Since a consensual endogenous control for miRNA expression in rectal tissue has still not been
determined, normalization was performed with hsa-miR-484 (Assay ID 478308_mir) for tissue miRNA
expression analysis. In our previous retrospective study miR-484 was identified as the most stably
expressed miRNA with the lowest expression variability when compared with mir-1228-5p, miR-345-5p,
miR-103a-3p and the small nuclear (snRNA) U6 and RNU6B, considered endogenous controls for
CRC tissues and/or serum. For serum miRNA expression analysis, normalization was performed
with cel-mir-39-3p (Assay ID 478293_mir). Expression levels were calculated by the threshold cycle
(2−∆∆Ct method), when amplification values were detected. Due to lack of amplification values of
miRNAs detected for all tissues, a variable number of samples have been included in each tissue
miRNA expression profile. To determine fold change, pre-CRT non-neoplastic tissue and pre-CRT
plasma samples were used as controls in tissue and plasma expression analysis, respectively. Fold
change values were calculated as the ratio between miR-21 levels in tissue or plasma and the mean of
the controls’ values.
4.7. Statistical Analysis
miRNA expression was analyzed using the Graph Pad Prism software package, version 7.0
(GraphPad software Inc., San Diego, CA, USA). Normal distribution was determined using the
D’Agostino & Pearson omnibus test. Statistical differences between patient groups in plasma expression
data were evaluated by two-tailed non-parametric Mann–Whitney U test, whereas tissue expression
data was analyzed using the one-way analysis of variance (ANOVA) Kruskal–Wallis non-parametric
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Dunn’s multiple comparison test. Spearman correlation coefficient was used to test the correlation
between plasma and tissue miRNA expression levels. Using contingency tables odds ratio (OR)
were estimated and the p-value associated were obtained resorting to Fisher test. Receiver operating
characteristic curve (ROC) were used to calculate optimal cut-offs for miR-21 in pre-CRT normal,
tumor tissue and blood determined as the point closest to the top left part of the plot with perfect
sensibility and sensitivity. miR-21 was then dichotomized according to these cut-offs. Kaplan–Meier
survival curves were compared with Log-rank test and simple Cox proportional hazards models were
adjusted to analyze the association of each variable with disease free survival. Overall survival was
not possible to determine in this study due to the reduced number of deaths observed (ndeath = 3).
Data was analyzed with SPSS (IBM, version 20) and R (version 3.0.2). p ≤ 0.05 acknowledged statistical
significance. There was professional statistical review performed in this manuscript.
5. Conclusions
There is an urgent need for biomarkers of response to CRT. In this study, although the efficacy of
tissue and plasma miR-21 to differentiate responders from non-responders could not be demonstrated,
the odds of non-response in patients overexpressing miR-21 was increased, however, with no statistical
significance. The role of miR-21 as a predictive tool for pathological response in RC patients treated
with CRT needs to be established in larger cohorts. Confirmation as such would translate into clinical
application through inclusion in algorithms of treatment decision, allowing a better selection of
candidates for CRT.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/13/9/246/s1,
Figure S1: Correlation between pre- and post-CRT miR-21 expression in plasma and tumor tissue, Table S1:
Predictive value of miR-21 cut-off.
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